Generic bivalirudin approved in US

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Generic bivalirudin approved in US

Genéricos/Novedades | Posted 07/08/2015 0 Post your comment

US-based injectables and biosimilars specialist Hospira announced on 16 July 2015 the approval of its abbreviated new drug application (ANDA) for generic bivalirudin for injection by the US Food and Drug Administration (FDA).

The drug is a generic version of The Medicines Company’s Angiomax (bivalirudin), which is a direct thrombin inhibitor indicated for use in combination with aspirin as an anticoagulant in patients:

with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA)
undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) as in the REPLACE-2 study
with, or at risk of, heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS), undergoing PCI.

Hospira’s generic bivalirudin is available in a single-dose flip-top vial, which is the same format as the brand-name drug. However, in a good example of generics innovation, Hospira also plans to launch a differentiated presentation of the 250 mg generic bivalirudin in the company’s unique ADD-Vantage vial. The ADD-Vantage system, which is a standardized, ready-to-mix drug delivery system, allows for easier medication mixing.

The approval of Hospira’s ANDA is not good news for The Medicines Company, which only received approval for Angiomax in 2000 and who had expected its two patents (‘343 and ‘727) on the drug to protect it until January 2029 (including paediatric exclusivity).

Sales of Angiomax in 2014 in the US were approximately US$500 million.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Hospira